×

NeoStem Announces Licensing of Patent Portfolio From The Rockefeller University Expanding Its Cancer Immunotherapy Intellectual Property Portfolio

NEW YORK, Sept. 11, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that the Company has entered into an exclusive license agreement with The Rockefeller University for patented technologies that further expand the Company's intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program.

The discovery of dendritic cells in 1973, resulting in a 2011 Nobel Prize in Physiology or Medicine, bridged the two principal aspects of immunity (innate and adaptive) first defined by Nobel Prize recipients in Physiology or Medicine in 1908. It was subsequently proved that dendritic cells, part of the innate immune system, orchestrate the immune response to specific antigens by absorbing antigens and, when activated, present the specific antigens to B and T cells that result in antigen specific adaptive immunity. The Rockefeller University patents licensed by NeoStem are titled: "Methods for use of Apoptotic Cells to Deliver Antigen to Dendritic Cells for Induction or Tolerization of T Cells," (inventors: Matthew Albert, Nina Bhardwaj, Ralph M. Steinman, Kayo Inaba and Robert Darnell). Studies showed that dendritic cells can be removed from the body in their inactive form, loaded with antigens and then re-infused and activated leading to an antigen specific immune response, including immune responses directed against cancer antigens.

"By licensing these patents that relate to NeoStem's DC/TC (dendritic cell/tumor cell) technology, which technology was acquired by us through the California Stem Cell, Inc. acquisition in May 2014, NeoStem continues to look proactively for opportunities to expand and defend its technology platform as we simultaneously plan to initiate our Phase 3 Intus clinical study that will investigate our DC/TC technology in metastatic melanoma this year," commented Dr. Andrew L. Pecora, Chief Visionary Officer of NeoStem.

This additional intellectual property from The Rockefeller University expands the breadth of the Company's already comprehensive Targeted Cancer Immunotherapy Program patent portfolio, which portfolio includes inventions relating to critical aspects of a dendritic cell-based therapy, such as novel antigen-presenting cancer vaccines, stem cell growth media, and methods to produce the high purity cancer initiating (stem) cells that provide the critical antigen array with which the vaccine's dendritic cells are pulsed.

About NBS20

NeoStem expects to initiate a pivotal Phase 3 clinical trial for NBS20, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. The goal of the therapy is to eliminate or neutralize the tumor cells that are responsible for recurrence after medically induced tumor regression after a patient has already undergone other treatments which may have reduced tumor size, but failed to entirely eliminate the cancer. NBS20 has been the subject of compelling trial results for the treatment of metastatic melanoma. As a result, NBS20 has been approved to enter a Phase 3 clinical trial with Special Protocol Assessment (SPA) and received Fast Track designation for metastatic melanoma, as well as Orphan Drug designation.

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Cancer Immunotherapy Program (including whether or not NBS20 will successfully be developed to treat metastatic melanoma or any other cancer indications), Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: mrice@lifesciadvisors.com Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com

Source:NeoStem Inc.